Claims
- 1. A pharmaceutical composition having dopamine agonist activity comprising a nontoxic but effective therefor quantity of a compound of the structural formula: ##STR4## in which R is amino, lower alkylamino, di-lower alkyl amino, di-N-allylamino or N-allyl-N-lower alkyl amino and n is an integer of 1-3; or a pharmaceutically acceptable, acid addition salt thereof, combined with a pharmaceutical carrier in dosage unit form.
- 2. The composition of claim 1 in which the compound is 4-(di-n-propylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
- 3. The composition of claim 1 in which the compound is a 4-(aminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
- 4. The composition of claim 1 in which the compound is 4-(di-allylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
- 5. The composition of claim 2 in which the dopamine agonist activity is manifested in anti-anginal pectoris activity.
- 6. The composition of claim 3 in which the dopamine agonist activity is manifested by beneficial treatment of congestive heart failure.
- 7. The method of producing dopamine agonist activity in a subject in need thereof comprising administering orally or parenterally an effective therefor, nontoxic quantity of a compound of the structural formula: ##STR5## in which R is amino, lower alkylamino, di-lower alkylamino, di-N-allylamino or N-allyl-N-lower alkyl amino and n is an integer of 1-3; or a pharmaceutically acceptable, acid addition salt thereof, combined with a pharmaceutical carrier in dosage unit form.
- 8. The method of claim 7 in which the compound is 4-(di-n-propylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
- 9. The method of claim 7 in which the compound is a 4-(aminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
- 10. The method of claim 7 in which the compound is 4-(di-allylaminoethyl)-7-hydroxy-2(3H)-indolone or a pharmaceutically acceptable acid addition salt thereof.
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 180,551, filed Aug. 22, 1980, issued as U.S. Pat. No. 4,314,944 on Feb. 9, 1982.
Non-Patent Literature Citations (1)
Entry |
Cavero et al., Life Science, vol. 31, pp. 1059-1069, 1982. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
180551 |
Aug 1980 |
|